FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-028							
Estimated average bu	ırden							
hours per response	0							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Typ	e Responses)															
1. Name and Address of Reporting Person * DELUCCIA ROBERT J				2. Issuer Name and Ticker or Trading Symbol Acurx Pharmaceuticals, Inc. [ACXP]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner				
	*	(First) RMACEUTICAI E		3. Date of 07/27/2			ansact	ion (M	Month/	Day/Y	ear)		Officer (give	title below)	Other	(specify belo	w)
(Street) STATEN ISLAND, NY 10305				4. If Amendment, Date Original Filed(Month/Day/Year)							ny/Year)	_X_	6. Individual or Joint/Group Filing(Check Applicable Line) X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person				
	(City) (State) (Zip)				Table I - Non-Derivative Securities Acqui							Acquired	lired, Disposed of, or Beneficially Owned				
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year	2A. Deemed Execution Date, if ir) any (Month/Day/Year		Date, if	(Instr. 8)		(A) or Disposed of			f (D) Ow Tra			d (Form:	7. Nature of Indirect Beneficial	
					y/ i eai)			V	Amou	nt (A) or (D)	Price	u. 3 and 4)				Ownership (Instr. 4)	
Common	Stock		07/27/2022				F	•		19,73	(/ I A	\$ 3.8 1,0	51,198])	
Common	Stock											3,8	47		1		By spouse
			Table II					quired	l, Disp	osed (of, or Benefi	icially Owi					
1. Title of Derivative Security	2. Conversion		3A. Deemed Execution Date, if	(<i>e.g.</i> , pt	uts, c	alls, wa 5. Num	rrants ber vative	quired s, opti 6. Da Expir	n this curre d, Disp ions, co ate Exertaion	form ently osed o onvert	are not recvalid OMB of, or Benefitible securite ole and	quired to control n icially Own ies)	respond u umber. ned d Amount	8. Price of	9. Number o Derivative Securities	(s) 10.	11. Natur of Indirec Beneficia
(Instr. 3)	Price of Derivative Security		(Month/Day/Year)				ed (A) osed	A) ((Instr. 3 a		(Instr. 5)	Beneficially Owned Following Reported Transaction(s	Derivati Security Direct (or Indire s) (I)	Ownersh: (Instr. 4)
				Code	v	(A)	(D)	Date Exerc	cisable		xpiration ate	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4))
Warrants for Common Stock	\$ 3.55	07/27/2022		P		19,73	7	01/2	27/20	23 0	1/27/2024	Commo Stock	n 19,737	\$ 0	19,737	D	
Warrants for Common Stock	\$ 3 55	07/27/2022		P		19,73	7	01/2	27/20	23 0	1/27/2028	Commo Stock	n 19,737	\$ 0	19,737	D	

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
DELUCCIA ROBERT J						
C/O ACURX PHARMACEUTICALS, INC.,	X	X				
259 LIBERTY AVENUE						
STATEN ISLAND, NY 10305						

Signatures

Signature of Reporting Person	Date		
	1		

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.